Skip to main content
Clinical Trials/NL-OMON33970
NL-OMON33970
Completed
Not Applicable

Assessment of tumor hypoxia in laryngeal cancer with 18F-fluoroazomycin arabinoside (18F-FAZA)-PET/CT scanning, oxygen-enhanced MRI (OE-MRI) and immunohistochemistry - 18F-FAZA-PET and OE-MRI in laryngeal cancer

niversitair Medisch Centrum Groningen0 sites12 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
12
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Patients with primary or recurrent squamous cell carcinoma of the larynx in whom total laryngectomy is considered the treatment of choice.
  • \* Glottic, subglottic or supraglottic larynxcarncer
  • \* Tumor volume more than 2 cm3
  • \* WHO performance: 0\-2
  • \* Patients older than 18 years
  • \* Written informed consent

Exclusion Criteria

  • \* Patient who does not sign the consent
  • \* Pregnancy
  • \* Patients younger than 18 years
  • \* Contraindications MRI, as
  • o Pacemakers / ICD's (cochlear implant, baclofenpump, insulin\-pump
  • o Severe renal insufficiency (eGFR \<\= 30\)
  • o Claustrophobia
  • o Patients with known gadolinium allergy

Outcomes

Primary Outcomes

Not specified

Similar Trials